|
|
| | L-Leucine, L-leucyl-L-seryl-L-leucyl-L-isoleucyl-L-threonyl-L-arginyl- Basic information |
| | L-Leucine, L-leucyl-L-seryl-L-leucyl-L-isoleucyl-L-threonyl-L-arginyl- Chemical Properties |
| density | 1.32±0.1 g/cm3(Predicted) | | pka | 3.38±0.10(Predicted) | | form | Solid | | color | White to off-white | | Sequence | Leu-Ser-Leu-Ile-Thr-Arg-Leu |
| | L-Leucine, L-leucyl-L-seryl-L-leucyl-L-isoleucyl-L-threonyl-L-arginyl- Usage And Synthesis |
| Uses | S7 is an IL-6 receptor antagonist and inhibits the binding between IL-6 and IL-6R. S7 can inhibit angiogenesis and tumor growth[1]. | | IC 50 | IL-6 | | References | [1] Janelle W. Salameh, et al. Targeted Interleukin-27 Gene Therapy Development for Disrupting Key Malignant Crosstalk between Metastatic Prostate Cancer and Bone. |
| | L-Leucine, L-leucyl-L-seryl-L-leucyl-L-isoleucyl-L-threonyl-L-arginyl- Preparation Products And Raw materials |
|